The non-invasive blood glucose monitoring system market would grow at a CAGR of 25% over the predicted time frame. The market is expected to increase in value from US$ 21.76 Mn in 2022 to US$ 129.75 Mn in 2030.

The on non-invasive blood glucose monitoring system Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

Download Free Sample@ https://www.precedenceresearch.com/sample/2405

A recent report provides crucial insights along with application based and Forecast information in the Global Non-invasive blood glucose monitoring system Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Non-invasive blood glucose monitoring system market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Non-invasive blood glucose monitoring system market are included as given below:

Non-invasive blood glucose monitoring system Market Key Players

• Abbott Laboratories
• Medtronic plc
• F. Hoffmann-La Roche Ltd.
• Ascensia Diabetes Care
• Dexcom, Inc.
• Sanofi Novo Nordisk
• Insulet Corporation
• Ypsomed Holdings
• Glysens Incorporated

Market Segments

By Technology

• Spectroscopy 
• Electromagnetic 
• Microwave 
• Ultrasonic 
• Thermal 
• Others

By End User

• Hospitals
• Homecare
• Clinics

By Modality

• Non wearable
• Wearable
• Invasive
• Non-invasive

By Distribution Channel

• Retail sales
• Institutional sales

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

Report Objectives

• To define, describe, and forecast the global non-invasive blood glucose monitoring system market based on product, and region
• To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
• To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
• To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
• To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
• To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
• To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the non-invasive blood glucose monitoring system market

Table of Content

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Non-Invasive Blood Glucose Monitoring System Market 

5.1. COVID-19 Landscape: Non-Invasive Blood Glucose Monitoring System Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Non-Invasive Blood Glucose Monitoring System Market, By Technology

8.1. Non-Invasive Blood Glucose Monitoring System Market, by Technology, 2022-2030

8.1.1. Spectroscopy

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Electromagnetic

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Microwave

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Ultrasonic

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. Thermal

8.1.5.1. Market Revenue and Forecast (2017-2030)

8.1.6. Others

8.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Non-Invasive Blood Glucose Monitoring System Market, By End User

9.1. Non-Invasive Blood Glucose Monitoring System Market, by End User, 2022-2030

9.1.1. Others

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Homecare

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Homecare

9.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Non-Invasive Blood Glucose Monitoring System Market, By Modality 

10.1. Non-Invasive Blood Glucose Monitoring System Market, by Modality, 2022-2030

10.1.1. Homecare

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Homecare

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Invasive

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Non-invasive

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Non-Invasive Blood Glucose Monitoring System Market, By Distribution Channel 

11.1. Non-Invasive Blood Glucose Monitoring System Market, by Distribution Channel, 2022-2030

11.1.1. Retail sales

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Institutional sales

11.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Non-Invasive Blood Glucose Monitoring System Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Technology (2017-2030)

12.1.2. Market Revenue and Forecast, by End User (2017-2030)

12.1.3. Market Revenue and Forecast, by Modality (2017-2030)

12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Technology (2017-2030)

12.1.5.2. Market Revenue and Forecast, by End User (2017-2030)

12.1.5.3. Market Revenue and Forecast, by Modality (2017-2030)

12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Technology (2017-2030)

12.1.6.2. Market Revenue and Forecast, by End User (2017-2030)

12.1.6.3. Market Revenue and Forecast, by Modality (2017-2030)

12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Technology (2017-2030)

12.2.2. Market Revenue and Forecast, by End User (2017-2030)

12.2.3. Market Revenue and Forecast, by Modality (2017-2030)

12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Technology (2017-2030)

12.2.5.2. Market Revenue and Forecast, by End User (2017-2030)

12.2.5.3. Market Revenue and Forecast, by Modality (2017-2030)

12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Technology (2017-2030)

12.2.6.2. Market Revenue and Forecast, by End User (2017-2030)

12.2.6.3. Market Revenue and Forecast, by Modality (2017-2030)

12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Technology (2017-2030)

12.2.7.2. Market Revenue and Forecast, by End User (2017-2030)

12.2.7.3. Market Revenue and Forecast, by Modality (2017-2030)

12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Technology (2017-2030)

12.2.8.2. Market Revenue and Forecast, by End User (2017-2030)

12.2.8.3. Market Revenue and Forecast, by Modality (2017-2030)

12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Technology (2017-2030)

12.3.2. Market Revenue and Forecast, by End User (2017-2030)

12.3.3. Market Revenue and Forecast, by Modality (2017-2030)

12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Technology (2017-2030)

12.3.5.2. Market Revenue and Forecast, by End User (2017-2030)

12.3.5.3. Market Revenue and Forecast, by Modality (2017-2030)

12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Technology (2017-2030)

12.3.6.2. Market Revenue and Forecast, by End User (2017-2030)

12.3.6.3. Market Revenue and Forecast, by Modality (2017-2030)

12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Technology (2017-2030)

12.3.7.2. Market Revenue and Forecast, by End User (2017-2030)

12.3.7.3. Market Revenue and Forecast, by Modality (2017-2030)

12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Technology (2017-2030)

12.3.8.2. Market Revenue and Forecast, by End User (2017-2030)

12.3.8.3. Market Revenue and Forecast, by Modality (2017-2030)

12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Technology (2017-2030)

12.4.2. Market Revenue and Forecast, by End User (2017-2030)

12.4.3. Market Revenue and Forecast, by Modality (2017-2030)

12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Technology (2017-2030)

12.4.5.2. Market Revenue and Forecast, by End User (2017-2030)

12.4.5.3. Market Revenue and Forecast, by Modality (2017-2030)

12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Technology (2017-2030)

12.4.6.2. Market Revenue and Forecast, by End User (2017-2030)

12.4.6.3. Market Revenue and Forecast, by Modality (2017-2030)

12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Technology (2017-2030)

12.4.7.2. Market Revenue and Forecast, by End User (2017-2030)

12.4.7.3. Market Revenue and Forecast, by Modality (2017-2030)

12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Technology (2017-2030)

12.4.8.2. Market Revenue and Forecast, by End User (2017-2030)

12.4.8.3. Market Revenue and Forecast, by Modality (2017-2030)

12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Technology (2017-2030)

12.5.2. Market Revenue and Forecast, by End User (2017-2030)

12.5.3. Market Revenue and Forecast, by Modality (2017-2030)

12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Technology (2017-2030)

12.5.5.2. Market Revenue and Forecast, by End User (2017-2030)

12.5.5.3. Market Revenue and Forecast, by Modality (2017-2030)

12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Technology (2017-2030)

12.5.6.2. Market Revenue and Forecast, by End User (2017-2030)

12.5.6.3. Market Revenue and Forecast, by Modality (2017-2030)

12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 13. Company Profiles

13.1. Abbott Laboratories

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Medtronic plc

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. F. Hoffmann-La Roche Ltd.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Ascensia Diabetes Care

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Dexcom, Inc.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Sanofi Novo Nordisk

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Abbott

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Ypsomed Holdings

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Glysens Incorporated

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: [email protected]

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com